Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis a mixed treatment comparison
Gespeichert in:
| Veröffentlicht in: | The European journal of health economics |
|---|---|
| Weitere Verfasser: | , , , , |
| Format: | UnknownFormat |
| Sprache: | eng |
| Veröffentlicht: |
2014
|
| Schlagworte: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Tag hinzufügen | Titel | Jahr | Band |
|---|---|---|
| Patient-reported outcomes : opportunities and challenges in Central Europe | 2019 | Volume 20, supplement 1 (June 2019) |
| Biological and biosimilar therapies in inflammatory conditions : challenges for the Central and Eastern European countries | 2013 | 15.2014, Suppl. 1 |
| The development of new research methods for the valuation of EQ-5D-5L | 2013 | 14.2013, Suppl. 1 |
| Special issue on economic evaluation | 2010 | 11.2010,1 |
| The cost of multiple sclerosis in Europe : costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis | 2006 | 7.2006, Suppl. 2 |
| Health economics without frontiers : 6th European Conference on Health Economics July 6-9, 2006 - Budapest, Hungary ; abstracts, oral presentations, poster presentations | 2006 | 7.2006, Suppl. 1 |
| Health outcomes in schizophrenia : = Gesundheitsökonomische Aspekte bei der Behandlung schizophrener Patienten | 2002 | 3.2002,Suppl. 2 |